What are the current and emerging strategies to improve low HDL-C levels?
A: Dyslipidemia is a well-known risk factor for coronary heart disease (CHD). Although decreasing low-density lipoprotein cholesterol (LDL-C) levels has long been the primary objective of the management of this disorder, emphasis has also been placed on finding new therapeutic targets as a means to further decrease cardiovascular risk, including agents that raise high-density lipoprotein cholesterol (HDL-C). Low HDL-C, which was previously defined as < 35 mg/dl but recently changed to < 40 mg/dl, is classified as a major risk factor for CHD, whereas high HDL-C (? 60 mg/dl) is beneficial and considered a negative risk factor.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
